1 / 95

FDA Advisory Panel March 5, 2002

Medtronic InSync ® ICD Cardiac Resynchronization System. FDA Advisory Panel March 5, 2002. Agenda. Introduction and Background . William T. Abraham, MD. Introduction.

celestyn
Download Presentation

FDA Advisory Panel March 5, 2002

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medtronic InSync® ICD Cardiac Resynchronization System FDA Advisory Panel March 5, 2002

  2. Agenda

  3. Introduction and Background William T. Abraham, MD

  4. Introduction • Over a third of moderate to severe heart failure patients (in NYHA Functional Class III or IV) have ventricular dysynchrony, evidenced by a QRS duration  130 ms1 • Associated with • Limited exercise tolerance • Impaired quality of life and functional capacity • Poor left ventricular systolic function2 1 Aaronson KD, et al. Circulation 1997; 95:2660-2667. 2 Zardini M, et al. Eur Heart J 2000; 2(Suppl J): J16-J22

  5. InSync Study Design Implant Attempt Successful Implant Pre-discharge Randomization Baseline  1 week Stable Medical Therapy Double Blinded Control CRT 1, 3, 6 Month Follow-up 1, 3, 6 Month Follow-up • Control: VDI mode • Treatment (CRT):VDD mode CRT CRT Long term follow up every 6 months

  6. InSync Study Primary Endpoints* * PMA# P010015, approved 8/28/01

  7. Endpoint Control CRT P value Peak VO2 (ml/kg/min) 0.1 1.0 0.038 Exercise Time (sec) 12 85 <0.001 Composite Response (%) 42,35,23 66,20,14 <0.001 InSync Study Secondary Clinical Endpoints

  8. InSync Primary Safety Results Summary Achieved all primary 6-month safety objectives including: • Implant success 6-month device related complications attributed to: • InSync Model 8040 • Attain Models 2187 and Model 2188 LV leads • InSync system • Attain Models 2187 and 2188 LV lead 6-month pacing threshold

  9. —Control 231 209 197 178 157 150 62 — CRT 230 219 211 184 162 157 73 InSyncDeath or Worsening Heart Failure RequiringHospitalization or IV Medications P = 0.02 CRT Control Patients At Risk

  10. Combining Resynchronization and ICD Function in a Single Device • Model 7272 InSync ICD • Dual-chamber VT and VF detection • Antitachycardia (ATP) pacing, cardioversion and defibrillation VT and VF therapies • Simultaneous biventricular pacing • RV sensing only

  11. Study Design, Methodology andPatient Population James B. Young, MD

  12. Entry Criteria • Chronic heart failure •  18 years of age • NYHA Functional Class II, III or IV • QRS duration  130 ms • LVEF  35% • LVEDD  55 millimeters (echo measure) • Stable HF medical regimen for  1 month • ACE-I or substitute, if tolerated • β-blocker - stable regimen for  3 months • Indication for an ICD

  13. InSync ICD Study Design Implant Attempt Successful Implant Pre-discharge Randomization Baseline  1 week Stable Medical Therapy Double Blinded Control CRT 1, 3, 6 Month Follow-up 1, 3, 6 Month Follow-up • Control: DDI mode • Treatment (CRT):DDD mode • ICD active in all patients • Heart failure medication stability maintained CRT CRT Long term follow up every 6 months

  14. Timing of Baseline Tests

  15. Study Features to Maintain the Blind • Blinded: • Patients (study ID card) • Heart failure staff • Listed on study blinding log • Blinded to ECGs • Conducted QOL, 6 minute hall walk, patients global assessment, NYHA classification and HF exam • Events Classification Committee • Unblinded: • EP staff • Listed on study blinding log • Viewed ECGs, device printouts, etc • Data placed into secure study envelopes

  16. Primary Safety Objectives • InSync ICD-related complication-free survival at 3 months • Attain Model 4189 LV lead-related complication-free survival at 6 months • Attain Model 2187/2188 LV lead- related complication-free survival at 6 months • InSync ICD system-related complication-free survival at 6 months

  17. Secondary Safety Objectives • Characterize patient survival • Characterize complication events • Characterize observation events

  18. Lead Effectiveness Objectives • Implant success • Evaluate the electrical performance of the Model 4189 LV lead • Evaluate the electrical performance of the Model 2187 and Model 2188 LV leads

  19. Evaluation of Integrity of ICD Function • Spontaneous VT/VF therapy effectiveness • Comparison of VT/VF event rates in the control and treatment arms • ATP therapy efficacy with biventricular pacing • Implant ventricular defibrillation criterion

  20. Primary Effectiveness Endpoints • As pre-specified in the investigational plan for NYHA Class III and IV patients, the following change from baseline to 6-month visit between control and treatment groups in: • Quality of life (MLWHF Questionnaire) • NYHA class • 6-minute hall walk distance • As pre-specified in the investigational plan, all 3 endpoints must be met at P < 0.05, or 2 met at P < 0.025, or 1 met at P < 0.0167

  21. Secondary Effectiveness Endpoints Clinical endpoints • Exercise performance • Clinical composite response • Health care utilization Physiological variables • Echocardiographic variables • QRS duration • Neurohormonal variables

  22. Study Milestones PMA Update submitted November 9, 2001 PMA submitted May 3, 2001 1st implant October 4, 1999 100 NYHA Class III & IV 6-month visitsMarch, 2001 224 NYHA Class III & IV 6-month visitsOctober, 2001

  23. Patient Disposition As pre-specified in the I.P., data from NYHA Class III/IV patients are discussed in this presentation Implant Attempts n=636 NYHA Class III/IV n=421 NYHA Class II n=215 Randomized n=362 Randomized n=192 Control n=176 CRT n=186 Control n=106 CRT n=86

  24. Patient Disposition Implant Attempts n=421 Unsuccessful Implants n=50 Implant Success n=371 Not Randomized n=9 Randomized n=362 Control n=176 CRT n=186

  25. Patient Disposition Control n = 176 CRT n = 186

  26. Methodology Overview • Safety Data • As pre-specified in the investigational plan, data from NYHA Class II, III and IV patients were submitted to FDA for the primary safety objectives • At FDA’s request, safety data from NYHA Class III and IV patients only are included in the Panel Pack and in this presentation

  27. Methodology Overview • Efficacy Data • The investigational plan pre-specified that the primary efficacy analysis was to be based on patients with paired data at 6 months, excluding crossovers • Results presented are based on an intent-to-treat analysis for patients with paired data at 6 months, including crossovers • Results of the pre-specified crossover excluded and last-observation-carried forward analyses will also be summarized

  28. Patient Demographics

  29. Patient Demographics

  30. Safety Results Angel R. Leon, MD

  31. Primary Safety Objectives • InSync ICD-related complication-free survival at 3 months • Attain Model 4189 LV lead-related complication-free survival at 6 months • Attain Model 2187/2188 LV lead- related complication-free survival at 6 months • InSync ICD system-related complication-free survival at 6 months

  32. Secondary Safety Objectives • Characterize patient survival • Characterize complication events • Characterize observation events

  33. Lead Effectiveness Objectives • Implant success • Evaluate the electrical performance of the Model 4189 LV lead • Evaluate the electrical performance of the Model 2187 and Model 2188 LV leads

  34. Evaluation of Integrity of ICD Function • Spontaneous VT/VF therapy effectiveness • Comparison of VT/VF event rates in the control and treatment arms • ATP therapy efficacy with biventricular pacing • Implant ventricular defibrillation criterion

  35. Lead Placement and LV Venous Anatomy A. Lateral (marginal) cardiac vein B. Postero-lateral cardiac vein C. Posterior cardiac vein D. Middle cardiac vein E. Great cardiac vein A • Attain LV Model 4189 • Transvenous, 4 French • Stylet/catheter Delivered • Unipolar B C E D

  36. Adverse Event Definitions • Complication: An adverse event requiring invasive intervention or that results in the death of or serious injury to the patient or in the termination of a significant device function • Observation: An adverse event not requiring invasive intervention or resolves spontaneously • System-related complication: A device-related complication that occurs after the initially implanted functioning system, comprised of: Model 7272 InSync ICD, a Model 4189, 2187 or 2188 LV lead, and RA and RV leads

  37. Implant Success Patient Implant Attempts n=421 Unsuccessful Implants n=50 Implant Success n=371 • Implant success defined per the protocol as a successfully placed LV lead.

  38. Unsuccessful Implants (n=50) * Not mutually exclusive

  39. Adverse Events During the Implant Procedure

  40. Resolution of Adverse Events During the Implant Procedure *Categories not mutually exclusive.

  41. Resolution of Implant Dissection/Perforation Events 432 implant attempts 22 events (22 patients) No patient deaths related to these events.

  42. Primary Safety Objective 1: Freedom From InSync ICD Related Complications at 3 Months • 371 patients implanted • 7 complications in 7 patients • Observed 3-month rate = 98.6% • Lower 95% confidence bound = 97.6% • Performance objective: 95% LCB  89% Performance Objective

  43. Freedom From InSync ICD Related Complications at 3 Months 371 patients implanted 7 events (7 patients)

  44. Primary Safety Objective 2: Freedom From Attain Model 4189 LV Lead-Related Complications at 6 Months • 315 patients implanted • 49 events (in 44 patients) • Observed 6-month rate = 85.1% • Lower 95% confidence bound = 81.7% • Performance objective: 95% LCB  75% Performance Objective

  45. Freedom From Attain Model 4189 LV Lead-Related Complications at 6 Months 315 patients implanted 49 events (44 patients) * Not mutually exclusive

  46. Attain Model 4189 LV Lead Related Complication Event Resolution * Not mutually exclusive

  47. Primary Safety Objective 3:Freedom From Attain Model 2187/2188 LV Lead-Related Complications at 6 Months • 56 patients implanted • 5 events in 5 patients • Observed 6-month rate = 89.9% • Lower 95% confidence bound = 82.9% • Performance objective: 95% LCB  75% Performance Objective

  48. Freedom From Attain Model 2187/2188 LV Lead-Related Complications at 6 Months 56 patients implanted 5 events (5 patients)

  49. Primary Safety Objective 4:InSync ICD System-Related Complications at 6 Months • 371 patients implanted • 79 events in 65 patients • Observed 6 month rate = 81.1% • Lower 95% confidence bound = 77.6% • Performance objective: 95% LCB  67% Performance Objective

  50. Primary Safety Results: Summary All primary safety objectives satisfied • Device-related complications attributed to: • InSync ICD Model 7272 • Attain Models 4189, 2187 and 2188 leads • InSync ICD system

More Related